Impact BioMedical Inc.
IBO
Get informed when a big investor buys or sells
+ FollowMarket Cap$49.61M
Close$
$-0.00
100.3% downside
Current Fair Value
100.3% downsideOvervalued by 100.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $49.61 Million |
|---|---|
| Enterprise Value | $49.60 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 2.73 |
| Outstanding Shares | 107,821,231 |
Return
| Return on Equity | 7.33% |
|---|---|
| Return on Assets | 4.71% |
| Return on Invested Capital | 14.01% |
Valuation & Multiples
| P/E Ratio | -4.71 |
|---|---|
| PEG | 4.96 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1417.1 |
| Enterprise Value to EBIT | 24.09 |
| Enterprise Value to Net Income | 62 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.45%▼ 1.11% |
|---|---|
| Total Invested | $2.23M▲ 207.56% |
| Investors Holding | 19▼ 3.00% |
ESG Score
No data
About Impact BioMedical Inc.
2 employees
CEO: Mr. Frank D. Heuszel Esq., J.D. Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced po...